Industry

SAN DIEGO–(BUSINESS WIRE)–Doctible, a leader in patient engagement and practice growth solutions, today announced the launch of two powerful additions to its platform: Patient Link and Doctible Websites. Designed to stimulate growth, without adding additional work for practice owners or their teams, these new solutions simplify operations, strengthen patient connections, and promote profitability. Patient Link … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and Geographical Regions” report has been added to ResearchAndMarkets.com’s offering. The global AAV vector market estimated to be 3.6 billion in the current year and USD 6.0 billion … [Read more…]

The panel, entitled “Mitigating Tissue Damage in Radiation Oncology and Inflammation in Pulmonary Disease: Targeting Pathways of Tissue Injury and Inflammatory Response,” will explore advances in unmet medical needs for oncology-related radiation exposure and pulmonary disease-related inflammation MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel approaches to tissue protection in oncology-related radiation … [Read more…]

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer’s disease PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Alzheimers—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration … [Read more…]

Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the … [Read more…]

Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders Company’s total cash position expected to be approximately $70 million following closing VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–#cyclopure–Kurita America Inc., a global leader in water treatment solutions, and Cyclopure, an innovator in advanced adsorbent technologies, today announced their expanding partnership to deliver the most advanced and sustainable solution for removing per- and polyfluoroalkyl substances (PFAS) from water with a completely regenerable material. With Cyclopure’s patented DEXSORB® technology and Kurita’s expertise in … [Read more…]

CHICAGO–(BUSINESS WIRE)–Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, is providing estimated financial performance for the second quarter of 2025 compared to the prior year, details about its recent financing activities, and reaffirmation of its outlook for the 2025 fiscal year. On Tuesday, September 2, longtime healthcare IT industry veteran Donald … [Read more…]

Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next … [Read more…]